Here we provide evidence that the introduction of sulphadoxine/pyrimethamine as a first-line treatment for malaria in Papua New Guinea has induced a rapid increase in P. falciparum isolates harbouring the sulphadoxine-resistant dhps mutation, and that all mutants share a common resistance origin in our study area. This evidence concerns the gene DHPS and malaria.